Tamara N Shenkier

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi request reprint Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency
    Tamara N Shenkier
    Division of Medical Oncology, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, Canada V5Z 4E6
    J Clin Oncol 20:197-204. 2002
  2. ncbi request reprint The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency
    Tamara N Shenkier
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 103:1008-17. 2005
  3. ncbi request reprint Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group
    Tamara N Shenkier
    British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, V5Z 4E6, Canada
    J Clin Oncol 23:2233-9. 2005
  4. ncbi request reprint Unusual variants of primary central nervous system lymphoma
    Tamara N Shenkier
    Division of Medical Oncology, University of British Columbia, and British Columbia Cancer Agency, Vancouver Cancer Clinic, Vancouver, British Columbia, Canada V5Z 4E6
    Hematol Oncol Clin North Am 19:651-64, vi. 2005
  5. doi request reprint International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era
    Alden A Moccia
    British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3383-8. 2012
  6. doi request reprint Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma
    Abdulwahab J Al-Tourah
    Division of Medical Oncology, Fraser Valley and Vancouver Cancer Centers and the Department of Pathology and Biostatistics, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    J Clin Oncol 26:5165-9. 2008
  7. doi request reprint A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Breast Cancer 9:166-72. 2009
  8. ncbi request reprint Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases
    Richard Lester
    Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Leuk Lymphoma 45:1881-5. 2004
  9. ncbi request reprint International study on low-grade primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Neurol 59:755-62. 2006
  10. ncbi request reprint Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 111:1085-93. 2008

Detail Information

Publications10

  1. ncbi request reprint Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency
    Tamara N Shenkier
    Division of Medical Oncology, British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, Canada V5Z 4E6
    J Clin Oncol 20:197-204. 2002
    ..To evaluate clinical outcome of patients with limited-stage diffuse large-cell lymphoma (DLCL) treated with three cycles of chemotherapy followed by involved-region irradiation (IRRT)...
  2. ncbi request reprint The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency
    Tamara N Shenkier
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Cancer 103:1008-17. 2005
    ..The objective of this study was to evaluate the clinical outcome of a population-based cohort of immunocompetent patients with primary central nervous system lymphoma (PCNSL) treated with 3 different strategies over 13 years...
  3. ncbi request reprint Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group
    Tamara N Shenkier
    British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, V5Z 4E6, Canada
    J Clin Oncol 23:2233-9. 2005
    ..To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL)...
  4. ncbi request reprint Unusual variants of primary central nervous system lymphoma
    Tamara N Shenkier
    Division of Medical Oncology, University of British Columbia, and British Columbia Cancer Agency, Vancouver Cancer Clinic, Vancouver, British Columbia, Canada V5Z 4E6
    Hematol Oncol Clin North Am 19:651-64, vi. 2005
    ..Treatment options include irradiation and intrathecal or systemic chemotherapy. The features of PCNSL of T-cell origin and indolent B-cell PCNSL also are discussed...
  5. doi request reprint International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era
    Alden A Moccia
    British Columbia Cancer Agency and University of British Columbia, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3383-8. 2012
    ..The IPS has not been validated in a recently treated population in which outcomes have improved compared with historic results...
  6. doi request reprint Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma
    Abdulwahab J Al-Tourah
    Division of Medical Oncology, Fraser Valley and Vancouver Cancer Centers and the Department of Pathology and Biostatistics, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
    J Clin Oncol 26:5165-9. 2008
    ..To assess the incidence and predictive factors for development of transformed lymphoma in a population-based series of patients with follicular lymphoma (FL)...
  7. doi request reprint A phase II trial of a neoadjuvant platinum regimen for locally advanced breast cancer: pathologic response, long-term follow-up, and correlation with biomarkers
    Rinat Yerushalmi
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada V5Z 4E6
    Clin Breast Cancer 9:166-72. 2009
    ....
  8. ncbi request reprint Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases
    Richard Lester
    Department of Internal Medicine, University of British Columbia, Vancouver, British Columbia, Canada
    Leuk Lymphoma 45:1881-5. 2004
    ..We advocate a high index of suspicion for primary PBL or its recurrence in patients with HIV infection, a history of low CD4 counts or high viral load, and oral or gastrointestinal symptoms...
  9. ncbi request reprint International study on low-grade primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Neurol 59:755-62. 2006
    ..The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma...
  10. ncbi request reprint Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 111:1085-93. 2008
    ..Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma. Long-term survival is possible in some patients...